 Sigilon Therapeutics Inc NASDAQ: SGTX reported that fibrosed spheres were observed during a retrieval procedure in a patient in its Phase 12 study of SIG-001 in severe or moderately severe hemophilia A. The SIG-001 trial had been placed on FDA clinical hold following a serious adverse event report relating to the development of inhibitors to Factor VIII in one of three patients treated. 